Article
Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review.
Neuro-oncology - 1 Apr 2022
Andrews Lily J, Thornton Zak A, Saincher Saanwalshah S, Yao Ian Y, Dawson Sarah, McGuinness Luke A, Jones Hayley E, Jefferies Sarah, Short Susan C, Cheng Hung-Yuan, McAleenan Alexandra, Higgins Julian P T, Kurian Kathreena M
Abstract excerpt
BACKGROUND: Detailed prevalence estimates of BRAFV600 mutations and BRAF inhibitor (BRAFi) treatment responses in V600-mutant glioma will inform trial development. METHODS: Our systematic review analyzed overall prevalence of BRAFV600 mutations in glioma and BRAFi treatment response. RESULTS: Based on 13 682 patients in 182 publications, the prevalence of BRAFV600 in epithelioid glioblastoma (eGBM) was 69% [95%...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.